Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

Mahesh Swaminathan; Farhad Ravandi

doi:10.3324/haematol.2023.283120

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

Leukemia

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	2561-2563
Number of pages	3
Journal	Haematologica
Volume	108
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2023.283120
State	Published - Oct 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2023.283120

Cite this

@article{c8527e7222c74883b55ac17c98dd31d3,

title = "Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?",

author = "Mahesh Swaminathan and Farhad Ravandi",

year = "2023",

month = oct,

doi = "10.3324/haematol.2023.283120",

language = "English (US)",

volume = "108",

pages = "2561--2563",

journal = "Haematologica",

issn = "0390-6078",